Изменение относительного содержания интерлейкина-2 у больных диссеминированной меланомой в процессе вакцинотерапии

Голубцова Наталья Валерьевна, И. Н. Михайлова, К. А. Парсункова et al. · Российский биотерапевтический журнал · 2011

We have investigated the relative abundance of interleukin-2 (IL-2) in the serum of patients with disseminated malignant melanoma (n=48) during dendritic cell vaccine therapy. Depending on the baseline, patients were divided into two groups (with higher values of IL-2 and lower values) with respect to indicators in the control group of donors. The analysis was conducted in patient survival depending on the initial level of relative content of IL-2 in serum samples of patients in both groups. Median survival for patients with initially elevated values of IL-2 was 34,0±4,6 months. In the group with lower values of IL-2, median survival was 24,0±16,7 months (p=0,131). Established increase in the relative content of IL-2 in 85.4% of patients during treatment.

Cited by 0 works.

Authors